[New antithrombotic drugs].
Taliani
M R
MR
Agnelli
G
G
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D000991:Antithrombins / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D003871:Dermatan Sulfate / Q000627:therapeutic use; D000077542:Eptifibatide; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D010446:Peptide Fragments / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010865:Pilot Projects; D010875:Pipecolic Acids / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013449:Sulfonamides
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D000991:Antithrombins; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006629:Hirudins; D007140:Immunoglobulin Fab Fragments; D010446:Peptide Fragments; D010455:Peptides; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D013449:Sulfonamides; D003871:Dermatan Sulfate; D001120:Arginine; C031942:argatroban; D000077542:Eptifibatide; C074619:bivalirudin; D000077284:Abciximab